TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET
Company Participants
Jenna Bosco – Senior Vice President of Corporate Communications
Michael Weiss – Chairman, Chief Executive Officer
Adam Waldman – Chief Commercialization Officer
Sean Power – Chief Financial Officer
Conference Call Participants
Ed White – H.C. Wainwright
Michael DiFiore – Evercore ISI
Eric Joseph – JP Morgan
Tara Bancroft – TD Cowen
Matt Kaplan – Ladenburg Thalmann
Mayank Mamtani – B. Riley Securities
Corinne Johnson – Goldman Sachs
Prakhar Agrawal – Cantor Fitzgerald
Roger Song – Jefferies
Operator
Greetings, and welcome to the TG Therapeutics’ Third Quarter Conference Call and Webcast. At this time, all participants are in a listen-only mode. [Operator Instructions] A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It’s now my pleasure to turn the call over to Jenna Bosco. Please go ahead.
Jenna Bosco
Thank you. Welcome, everyone, and thanks for joining us this morning. I’m Jenna Bosco. And with me today to discuss the third quarter 2024 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer.
Following our Safe Harbor statement, Mike will provide an overview of our recent corporate developments, Adam will share an update on our commercialization efforts, and Sean will give a summary of our financial results before turning the call over to the operator to begin the Q&A.
Before we begin, I’d like to remind everyone that we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about our anticipated future operating and financial performance, including sales performance, projected milestones, revenue guidance, development plans and expectations for our marketed products.
